Halozyme stock rises after winning injunction against Merck

A Dutch court ruled in favor of Halozyme Therapeutics, ordering Merck & Co. to halt sales of injectable Keytruda in eight European markets. The court found Merck infringed Halozyme's patent for a rapid drug delivery technology. Merck disputes the ruling and is reviewing its options. Keytruda SC is crucial for Merck's growth as patents on its original version expire later this decade.

Halozyme won a Dutch court order against Merck, halting the sale and production of Keytruda SC in eight European markets. The ruling found Merck infringed Halozyme's patent for under-the-skin drug delivery. Merck plans to evaluate next steps and disputes the decision. Halozyme has also sued Merck in the U.S. and Germany.

Tempus Inc. (TEM) expanded its collaboration with Moderna (MRNA) and Merck (MRK) to support the development of a cancer vaccine. Tempus will manage sample collection and provide NGS services. The company also partnered with Bristol Myers Squibb (BMY) to improve clinical trial design. Additionally, Tempus acquired Personalis (PSNL) for $1.5 billion to enhance cancer monitoring. TEM shares were down 1.94% to $70.58 at the time of publication.

Halozyme Therapeutics won a court order blocking Merck from manufacturing and distributing a formulation of its cancer drug, Keytruda SC, in several European markets. The Dutch patent court ruled Merck infringed Halozyme's patent, following a similar injunction in Germany. Merck disputes the ruling and plans to appeal.

Halozyme Therapeutics (HALO) announced a Dutch court ruled Merck (MRK) infringed its patent and barred sales of Keytruda SC in eight European markets. The injunction prohibits Merck from manufacturing, selling, or distributing the drug in those countries.

Halozyme Therapeutics' stock rose 0.8% after a Dutch court ruled Merck infringed its patent, halting Keytruda SC sales in eight European markets. The court also upheld the patent's validity. Halozyme also expanded its collaboration with argenx, increasing royalty and milestone revenue potential. H.C. Wainwright reiterated a Buy rating with a $115 price target. The stock's gains contrast with broader market declines, reflecting investor confidence in its ENHANZE technology and patent strategy.